ApoE-Deficient Mice Atherosclerotic Lesion Development in Inhibition of IL-17A Attenuates

Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.

OBJECTIVE Interleukin(IL)-17A, an inflammatory cytokine, has been implicated in atherosclerosis, in which inflammatory cells within atherosclerotic plaques express IL-17A. However, its role in the development of atheroscelrosis remains to be controversial. METHODS AND RESULTS To directly examine the role of IL-17A in atherosclerosis, we generated apolipoprotein E (ApoE)/IL-17A double-deficien...

The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment.

RATIONALE Atherosclerosis is a disease of large- and medium-sized arteries that is characterized by chronic vascular inflammation. While the role of Th1, Th2, and T-regulatory subsets in atherogenesis is established, the involvement of IL-17A-producing cells remains unclear. OBJECTIVE To investigate the role of the IL-17A/IL-17RA axis in atherosclerosis. METHODS AND RESULTS We bred apolipop...

Molecular Medicine The IL-17A/IL-17RA Axis Plays a Proatherogenic Role via the Regulation of Aortic Myeloid Cell Recruitment

Rationale: Atherosclerosis is a disease of largeand medium-sized arteries that is characterized by chronic vascular inflammation. While the role of Th1, Th2, and T-regulatory subsets in atherogenesis is established, the involvement of IL-17A-producing cells remains unclear. Objective: To investigate the role of the IL-17A/IL-17RA axis in atherosclerosis. Methods and Results: We bred apolipoprot...

Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice.

OBJECTIVE Caffeic acid phenethyl ester (CAPE), a natural flavonoid, specifically blocks activation of nuclear factor-kappaB (NF-kappaB). We examined the effects of oral CAPE supplementation on atherogenesis in apolipoprotein E-deficient (apoE-/-) mice. METHODS AND RESULTS Ten-week-old male apoE-/- mice were supplemented orally with CAPE (30 mg/kg body weight) for 12 weeks. At the end of admin...

Atherosclerotic Lesion Development in Inhibition of IL-17A Attenuates